47Sc as useful β−-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes

Katharina A. Domnanich1,2, Cristina Müller3,4, Martina Benešová3,4, Rugard Dressler1, Stephanie Haller3, Ulli Köster5, Bernard Ponsard6, Roger Schibli3,4, Andreas Türler1,2 and Nicholas P. van der Meulen1,3*

* Correspondence: nick.vandermeulen@psi.ch
1Laboratory of Radiochemistry, Paul Scherrer Institut, 5232 Villigen-PSI, Switzerland
3Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, 5232 Villigen-PSI, Switzerland
Full list of author information is available at the end of the article

Abstract

Background: Radiotheragnostics makes use of the same molecular targeting vectors, labeled either with a diagnostic or therapeutic radionuclide, ideally of the same chemical element. The matched pair of scandium radionuclides, 44Sc and 47Sc, satisfies the desired physical aspects for PET imaging and radionuclide therapy, respectively. While the production and application of 44Sc was extensively studied, 47Sc is still in its infancy. The aim of the present study was, therefore, to investigate and compare two different methods of 47Sc production, based on the neutron irradiation of enriched 46Ca and 47Ti targets, respectively.

Methods: 47Sc was produced by thermal neutron irradiation of enriched 46Ca targets via the 46Ca(n,γ)47Ca→47Sc nuclear reaction and by fast neutron irradiation of 47Ti targets via the 47Ti(n,p)47Sc nuclear reaction, respectively. The product was compared with regard to yield and radionuclidic purity. The chemical separation of 47Sc was optimized in order to obtain a product of sufficient quality determined by labeling experiments using DOTANOC. Finally, preclinical SPECT/CT experiments were performed in tumor-bearing mice and compared with the PET image of the 44Sc labeled counterpart.

Results: Up to 2 GBq 47Sc was produced by thermal neutron irradiation of enriched 46Ca targets. The optimized chemical isolation of 47Sc from the target material allowed formulation of up to 1.5 GBq 47Sc with high radionuclidic purity (>99.99%) in a small volume (~700 μL) useful for labeling purposes. Three consecutive separations were possible by isolating the in-grown 47Sc from the 46/47Ca-containing fraction. 47Sc produced by fast neutron irradiated 47Ti targets resulted in a reduced radionuclidic purity (99.95–88.5%). The chemical purity of the separated 47Sc was determined by radiolabeling experiments using DOTANOC achievable at specific activities of 10 MBq/nmol. In vivo the 47Sc-DOTANOC performed equal to 44Sc-DOTANOC as determined by nuclear imaging.

Conclusion: The production of 47Sc via the 46Ca(n,γ)47Ca nuclear reaction demonstrated significant advantages over the 47Ti production route, as it provided higher quantities of a radionuclidically pure product. The subsequent decay of 47Ca enabled the repeated separation of the 47Sc daughter nuclide from the 47Ca parent nuclide. Based on the results obtained from this work, 47Sc shows potential to be produced in suitable quality for clinical application.

(Continued on next page)
Keywords: $^{47}$Sc, Matched pairs, Theragnostics, Radionuclide production, $^{46}$Ca, $^{47}$Ti, Thermal and fast neutrons, SPECT/CT imaging

**Background**

Over the past few years, the concept of personalized medicine, where patient treatment is performed according to an individually tailored treatment regime, has gained much recognition (Kraeber-Bodere and Barbet 2014). In nuclear medicine, this approach is realized by exploiting diagnostic techniques, such as non-invasive imaging by means of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), together with individualized radiotherapeutic treatment (Velikyan 2012). The resulting combination became known as the theragnostic approach and comprises the use of the same molecular targeting vectors, labeled either with a diagnostic or therapeutic radionuclide (Baum and Kulkarni 2012). Ideally, the employed radionuclides represent a matched pair, where both are radioisotopes of the same chemical element. Only a limited number of matching radionuclides entail suitable decay characteristics for radiotheragnostic application (Rösch and Baum 2011); of those the radionuclides of scandium, $^{44}$Sc/$^{43}$Sc and $^{47}$Sc, are interesting candidates. Based on the physical and chemical characteristics, the $\beta^-$-emitter $^{47}$Sc is particularly interesting for radionuclide therapy, while the decay characteristics of $^{44}$Sc and $^{43}$Sc are well-suited for diagnostic PET imaging (Table 1) (Rösch 2012; Müller et al. 2014a, 2014b; Walczak et al. 2015).

This matched pair would present an attractive alternative to $^{68}$Ga and $^{177}$Lu, which are currently used in clinics for PET imaging and therapy, respectively (Oh et al. 2011). Ga(III) and Lu(III) can be coordinated by 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTA)-complexes (Majkowska-Pilip and Bilewicz 2011), however, they do not share the same coordination chemistry. Lu(III) is coordinated by all carboxyl groups of the octadentate DOTA (Viola-Villegas and Doyle 2009; Parus et al. 2015), while Ga(III) has a preference for the coordination number six, leaving two uncoordinated carboxyl groups in the Ga-DOTA-complex (Viola-Villegas and Doyle 2009; Majkowska-Pilip and Bilewicz 2011). As a result, these structural differences may have an influence on the radioconjugate’s chemical properties and, consequently, on the in vivo kinetics and receptor binding affinity (Reubi et al. 2000; Majkowska-Pilip and Bilewicz 2011). By using chemically identical radionuclides such as $^{44}$Sc/$^{47}$Sc–known to form stable complexes with DOTA–this limitation could be addressed.

The physical half-life of $^{44}$Sc of 3.97 h (recently re-determined as 4.04 h (Garcia-Torano et al. 2016), is almost 4-fold longer than that of $^{68}$Ga ($T_{1/2} = 68$ min) and, hence, allows its

| Table 1 | Nuclear data of theragnostic radionuclides for therapy and PET imaging |
|---------|-----------------------------------------------------------------|
|         | Therapeutic radionuclide | Diagnostic radionuclide (positron emitter) |
| $^{177}$Lu | 6.65 | 134 | 113 (6.4) 208 (11.0) | 68Ga | 1.13 | 830 (89) | 1077 (3.0) |
| $^{47}$Sc | 3.35 | 162 | 159 (68.3) | $^{46}$Sc | 4.04 | 632 (94) | 1157 (99.9) |
| $^{43}$Sc | 3.89 | 476 (88) | 372 (23.0) |

Intensities less than 5% were not considered
use with biomolecules with slower kinetics. Due to the possibility of shipping $^{44}\text{Sc}$-radio-
pharmaceuticals over long distances, it can also facilitate logistics as it would allow cen-
tralized production and distribution to remote hospitals (Chakravarty et al. 2014; van der
Meulen et al. 2015). The increased availability of $^{44}\text{Sc}$ has initiated a number of preclinical
in vitro and in vivo studies with DOTA-conjugated biomolecules (Müller et al. 2013a,
2013b; Hernandez et al. 2014) and, recently, labeling of NODAGA (1,4,7-triazacyclononane,1-
glutaric acid-4,7-acetic acid)-functionalyzed peptides and DTPA (N-[(R)-2-amino-3-(para-
thiocyanato-phenyl)propyl]trans-(S,S)-cyclohexane-1,2-diamine N,N,N’N’'-pentaacetic acid)-functionalyzed antibodies was also demonstrated (Chakravarty et al. 2014; Domnanich et al. 2016).

The emission of low-energy $\beta^-$-particles from $^{47}\text{Sc}$ ($E_{\text{av}} = 162$ keV, Table 1) is par-
ticularly interesting for targeted radionuclide therapy of small tumors and cancer me-
tastases, similar to the clinically-established $^{177}\text{Lu}$ ($E_{\text{av}} = 134$ keV, $T_{1/2} = 6.65$ d,
Table 1). Moreover, the shorter half-life of $^{47}\text{Sc}$ ($T_{1/2} = 3.35$ d) would encourage its use,
in conjunction with small molecules, with relatively fast pharmacokinetic profiles. In
analogy to $^{177}\text{Lu}$, the decay of $^{47}\text{Sc}$ is characterized by the co-emission of $\gamma$-rays with an
ideal energy ($E_\gamma = 159$ keV, Table 1) for SPECT imaging (Müller et al. 2014a).

The availability of high $^{47}\text{Sc}$ activity with adequate purity becomes a crucial issue for
the realization of more detailed preclinical investigations and future clinical applica-
tions. So far, successful production of $^{47}\text{Sc}$ was described by two different neutron in-
duced reactions: $^{47}\text{Ti}(n,p)^{47}\text{Sc}$ and $^{46}\text{Ca}(n,\gamma)^{47}\text{Ca} \rightarrow ^{47}\text{Sc}$ (Fig. 1) (Bartoš et al. 2012;
Müller et al. 2014a). To produce $^{47}\text{Sc}$ from $^{47}\text{Ti}$, fast neutrons ($E_n > 1$ MeV) are re-
quired, while the $^{46}\text{Ca}(n,\gamma)^{47}\text{Ca}$ reaction is induced by thermal neutrons ($E_n = 0.025$ eV)
(Bartoš et al. 2012). Proton irradiation of enriched $^{48}\text{Ti}$ targets made $^{47}\text{Sc}$ available via
the $^{48}\text{Ti}(p,2p)^{47}\text{Sc}$ nuclear reaction, however, too much of the long-lived $^{46}\text{Sc}$ was co-
produced (Srivastava 2012). An alternative $^{47}\text{Sc}$ production route considers photonu-
clear reactions on enriched $^{48}\text{Ti}$ and $^{48}\text{Ca}$ targets, respectively (Yagi and Kondo 1977;
Mamtimin et al. 2015; Rane et al. 2015; Starovoitova et al. 2015). So far only the former
route was studied in detail with enriched targets (Yagi and Kondo 1977), while for the
latter only natural target material was used for initial benchmark experiments.
The aim of the present study was to optimize the parameters of the previously-reported production process for $^{47}\text{Sc}$ from enriched $^{46}\text{Ca}$ targets (Müller et al. 2014a) in order to reproducibly obtain increased $^{47}\text{Sc}$ yields in a formulation allowing direct preclinical application after radiolabeling and to compare it with the method using $^{47}\text{Ti}$ as target material. $^{47}\text{Sc}$ labeling experiments with DOTANOC were performed as part of the quality control. In the second part of the study the stability of $^{47}\text{Sc}$-labeled DOTANOC was investigated and SPECT/CT imaging studies were performed in tumor-bearing mice to compare the performance of $^{47}\text{Sc}$-DOTANOC with the previously obtained PET images of the $^{44}\text{Sc}$-labeled counterpart. Moreover, comparison of SPECT images obtained with mice injected with $^{177}\text{Lu}$-DOTANOC were also performed.

**Methods**

**Chemicals**

Enriched $^{46}\text{CaCO}_3$ (83.09% $^{40}\text{Ca}$, 1.19% $^{42}\text{Ca}$, 0.36% $^{43}\text{Ca}$, 8.55% $^{44}\text{Ca}$, 5.00 ± 0.50% $^{46}\text{Ca}$, 1.81% $^{48}\text{Ca}$, Trace Sciences International, USA) was used as target material for thermal neutron irradiation. Enriched $^{47}\text{TiO}_2$ (0.41% $^{46}\text{Ti}$, 95.7 ± 0.3% $^{47}\text{Ti}$, 3.61% $^{48}\text{Ti}$, 0.15% $^{49}\text{Ti}$, 0.13% $^{50}\text{Ti}$, Isoflex, USA) was reduced to $^{47}\text{Ti}$ metal and used as target material for fast neutron irradiation. Prior to irradiation, a precursory scan for trace metals by ICP-OES (Perkin Elmer Optima 3000) was performed.

The chemical separation of $\text{Sc}$ from $\text{Ca}$ was performed on a $\text{N,N,N',N'}$-tetra-n-octyldiglycolamide, non-branched resin (DGA, particle size 50–100 μm, Triskem International, France). SCX cation exchange cartridges (100 mg Bond Elut SCX, particle size 40 μm, Agilent Technologies Inc., USA) or DGA extraction chromatographic resin were used for the preconcentration of $\text{Sc}$. Chemical separations were performed with MilliQ water, hydrochloric acid (HCl, 30% Suprapur, Merck KGaA, Germany) and sodium chloride (NaCl, Trace Select, ≥99.999%, Fluka Analytical, Germany). For the $^{47}\text{TiO}_2$ reduction process, calcium hydride ($\text{CaH}_2$, metals basis, Mg <1%, Alfa Aesar, Germany), argon (Ar, 99.9999%, Linde, Germany) and acetic acid ($\text{CH}_3\text{COOH}$, 100% Suprapur, Merck KGaA, Germany) were used. Nitric acid ($\text{HNO}_3$, 65% Suprapur, Merck KGaA, Germany) was required for the preparation of the $^{46}\text{Ca}$ targets. DOTANOC acetate was obtained from ABX GmbH, advanced biochemical compounds, Germany.

**Production of $^{47}\text{Sc}$ from enriched $^{47}\text{Ti}$**

The reduction of $^{47}\text{TiO}_2$ was performed at Helmholtz Center for Heavy Ion Research (GSI) in Darmstadt as described elsewhere (Lommel et al. 2014). Briefly, the enriched $^{47}\text{TiO}_2$ was combined with 40% surplus of calcium hydride and the reduction process was performed under constant argon flow at 900 °C for 1 h. Dilute acetic acid was used for the isolation of the reduced $^{47}\text{Ti}$ metal from the co-produced calcium oxide.

To prepare the targets, 0.6–19.9 mg reduced $^{47}\text{Ti}$ powder was placed in a quartz glass ampoule (Suprasil, Heraeus, Germany) and sealed. The targets were irradiated with neutrons at the spallation-induced neutron source, SINQ, at Paul Scherrer Institut (PSI) at a fast neutron flux (>1 MeV) of 3.3–3.5 × 10^{11} n cm^{-2} s^{-1} for 1.5–18.9 days and in the BR2 reactor at SCK.CEN, Mol, Belgium in a reflector channel at a fast neutron flux (>1 MeV) of 5.7 × 10^{13} n cm^{-2} s^{-1} for 7 days. $^{47}\text{Sc}$ was formed via the $^{47}\text{Ti}(n,p)^{47}\text{Sc}$ nuclear reaction with fast neutrons.
Production of $^{47}$Sc from enriched $^{46}$Ca

To prepare the targets, 65–91 mg enriched $^{46}$CaCO$_3$ powder was dissolved in concentrated nitric acid and evaporated to complete dryness at 60–70 °C. The $^{46}$Ca(NO$_3$)$_2$ residue was taken up in dilute nitric acid (~1 M HNO$_3$) and an aliquot of the aqueous solution (0.14–0.35 mg $^{46}$Ca) transferred into a quartz glass ampoule, evaporated to dryness and sealed. $^{47}$Sc was produced by the irradiation of the described $^{46}$Ca targets with thermal neutrons at the high flux reactor of Institut Laue-Langevin (ILL) in Grenoble, France at a thermal neutron flux of 1.0–1.4 × 10$^{15}$ n cm$^{-2}$ s$^{-1}$, for 4 to 11 days, and at the BR2 reactor at SCK.CEN, Mol, Belgium at a thermal neutron flux of 3.2 × 10$^{14}$ n cm$^{-2}$ s$^{-1}$ for 7 days, respectively. $^{47}$Sc was generated by the decay of the formed $^{47}$Ca (T$_{1/2} = 4.54$ d) occurring during the irradiation, but also after removal of the ampoule from the reactor.

Separation of $^{47}$Sc from $^{46}$Ca and $^{47}$Ca

The irradiated $^{46}$Ca ampoules were delivered to PSI several days post-irradiation (2.6–12.4 d) and the $^{47}$Sc separation was performed immediately, similarly to previously reported (Müller et al. 2014a). Each ampoule was transferred into a hot cell and the glass surface was cleaned twice with ~20 mL 1.0 M HCl and rinsed twice with ~20 mL MilliQ water. The crushing of the quartz glass ampoule was performed within a plastic target tube in a separate hot cell. Subsequently, the target tube containing the crushed ampoule was attached to the separation panel with the aid of manipulators. The design of the separation panel, including the adaptation of its operation inside the hot cell, was a crucial part of the method development (Fig. 2). The $^{46}$Ca(NO$_3$)$_2$ (~10–25 mg) from the ampoule was dissolved in 4 mL 3.0 M HCl and transferred from the target tube to the reaction vial. A system of syringes, peristaltic pumps and three-way valves (see schematic of the panel in Fig. 2) was used to transfer the reagents from outside into the hot cell. To ensure complete dissolution of the target material, the solution was pumped from the target tube to the reaction vial and back several times. The solution was loaded on a pre-conditioned DGA column (1 mL cartridge filled with 50–70 mg of DGA resin). A second rinse cycle of the crushed glass ampoule with 2.5 mL 3.0 M HCl ensured collection of final traces of the $^{47}$Sc activity, which were subsequently sorbed onto the DGA resin column. Radioactivity detection probes were attached in the vicinity of the target tube and the DGA column to follow the transfer of the $^{47}$Sc radioactivity. Further application of 2 mL 3.0 M HCl removed the stable $^{46}$Ca and radioactive $^{47}$Ca from the DGA resin. The entire Ca-containing effluent was collected in a separate vessel and kept for consecutive separation of further in-growing $^{47}$Sc from the decaying $^{47}$Ca. The sorbed $^{47}$Sc was eluted from the resin column with 4 mL 0.1 M HCl and sorbed on a second column containing SCX cation exchange resin (Method A). Alternately, the $^{47}$Sc-containing eluate was collected, acidified to yield a 3.0 M HCl solution and sorbed on a second, smaller DGA resin column (1 mL cartridge filled with 20–25 mg DGA resin) at a slow flow rate of ~0.3 mL/min (Method B), as described by Domnanich et al. (Domnanich et al. 2016). The elution of $^{47}$Sc from the second column was performed with 700 μL 4.8 M NaCl/0.1 M HCl (for Method A) and with 1.7 mL 0.05 M HCl (for Method B) via a separate valve. In order to collect $^{45}$Sc in a small volume, the 0.05 M HCl (Method B) was fractionized into three Eppendorf vials; the first contained ~700 μL and the other two ~500 μL each. Fractionized collection
was not necessary for Method A, as the highest proportion of the $^{47}$Sc radioactivity was trapped in a low quantity of eluate.

The renewed generation of $^{47}$Sc, by the decay of radioactive $^{47}$Ca in the Ca-containing fraction ($^{47}$Ca and stable $^{46}$Ca), enabled subsequent separations after a minimum in-growth time of 3 days.

**Radionuclidic purity**

To identify the nuclide inventory of the samples, $\gamma$-ray spectrometry with an N-type high-purity germanium (HPGe) coaxial detector (EURISYS MESURES, France) and the Ortec InterWinner 7.1 software were employed. The aliquot of $^{47}$Sc eluate was in the range of 3–15 MBq, while the entire neutron irradiated glass ampoules containing the $^{47}$Ti were used for the measurements. The counting time was determined by ensuring the measurement error was <4%. To determine small activities of long-lived radionuclidic impurities, $\gamma$-spectrometry measurements of the same samples were performed with an extensive counting time several days post-irradiation.

**Radiolabeling for quality control of the produced $^{47}$Sc**

After quantitative determination of the $^{47}$Sc activity in the eluate with a dose calibrator (ISOMED 2010, Nuclear-Medizintechnik Dresden, GmbH, Germany), the required activity for radiolabeling in 0.05 M HCl was withdrawn from the product vial and 0.5 M sodium acetate solution (pH 8) was added to the $^{47}$Sc eluate to obtain a pH value of ~4.5. DOTANOC (0.7 mM solution in MilliQ water) was added to the $^{47}$Sc solution (~50 MBq) to obtain a specific activity of 10–25 MBq/nmol (2–5 nmol DOTANOC). The reaction mixture was incubated at 95 °C for 15 min. The preparation of $^{177}$Lu-
DOTANOC (25 MBq/nmol) was carried out under standard labeling conditions (pH 4.5, 95 °C) using no carrier-added $^{177}$Lu (purchased from Isotope Technologies Garching GmbH, Germany) (Müller et al. 2013a).

High-performance liquid chromatography (HPLC, Merck Hitachi, LaChrom) with a C-18 reversed-phase column (Xterra™ MS, C18, 5 μm, 150 × 4.6 mm; Waters) was used for determination of the radiolabeled fraction of DOTANOC. The detection was performed with a UV (LaChrom L-7400) and radiodetector (Berthold, HPLC Radioactivity Monitor, LB 506B). The mobile phase consisted of MilliQ water containing 0.1% trifluoracetic acid (A) and acetonitrile (B) with a gradient of 95% A and 5% B to 20% A and 80% B, over a period of 15 min, at a flow rate of 1.0 mL/min.

In vitro stability of $^{47}$Sc- and $^{177}$Lu-labeled DOTANOC

The in vitro stability of $^{47}$Sc- and $^{177}$Lu-labeled DOTANOC (radiochemical purities >95%) was investigated in phosphate buffered saline (PBS, pH 7.4). An activity of 50 MBq of $^{47}$Sc- or $^{177}$Lu-DOTANOC was diluted with PBS (pH 7.4) to a total volume of 500 μL and incubated at room temperature for 3 days. Once every 24 h an aliquot was withdrawn to determine the integrity of the labeled compound by means of HPLC.

SPECT/CT imaging with $^{47}$Sc- and $^{177}$Lu-DOTANOC

In vivo experiments were approved by the local veterinarian department and conducted in accordance with the Swiss law of animal protection. Female, athymic nude mice (CD-1 nude) at the age of 5–6 weeks were obtained from Charles River Laboratories, Sulzfeld, Germany. AR42J cells (rat exocrine pancreatic tumor cells, European Collection of Cell Cultures ECACC, Salisbury, U.K.) were suspended in PBS (5 × 10^6 cells in 100 μL) and subcutaneously inoculated on each shoulder. SPECT/CT experiments were performed about 2 weeks after tumor cell inoculation, when the tumor reached a size of about 400 mm^3.

Imaging studies were performed using a small-animal SPECT camera (NanoSPECT/CT™, Mediso Medical Imaging Systems, Budapest, Hungary) as previously reported (Müller et al. 2014b). The energy peaks for the camera were set at 159.4 keV (± 10%) for the scans with $^{47}$Sc and 56.1 keV (± 10%), 112.9 keV (± 10%) and 208.4 keV (± 10%) for the scans with $^{177}$Lu. SPECT/CT scans were followed by CT scans. The images were acquired using Nucline Software (version 1.02, Bioscan Inc., Poway, California, US). The reconstruction was performed iteratively with HiSPECT software (version 1.4.3049, Scivis GmbH, Göttingen, Germany). SPECT and CT data were automatically co-registered and the fused datasets were analyzed with the VivoQuant post-processing software (version 2.50, inviCRO Imaging Services and Software, Boston, USA).

The mice were injected intravenously with $^{47}$Sc-DOTANOC (12 MBq, 1.2 nmol, 100 μL) and $^{177}$Lu-DOTANOC (40 MBq, 1.2 nmol, 100 μL), respectively. The in vivo SPECT/CT scans of 35 min duration were acquired 3 h after injection of $^{47}$Sc-DOTANOC. During the scans, the mice were anesthetized by inhalation of a mixture of isoflurane and oxygen. Post-mortem scans of 1.3–3.5 h were performed 6 h after injection of $^{47}$Sc- and $^{177}$Lu-DOTANOC. The SPECT acquisitions were performed in such a manner to obtain the same total number of counts for each scan.
Results

Production of $^{47}$Sc from $^{47}$Ti via the (n,p) reaction

The irradiation of enriched $^{47}$Ti targets at both SINQ and the BR2 reactor resulted in the formation of 0.07–4.9 MBq $^{47}$Sc at the end of irradiation (EOI). The respective $^{47}$Sc saturation yields were determined to be between 1.8 and 10.0 MBq $^{47}$Sc/mg $^{47}$Ti $10^{-13}$ n cm$^{-2}$ s$^{-1}$ (summarized in Table 2) by taking the irradiation time, mass of enriched $^{47}$Ti and fast neutron flux into consideration. $\gamma$-spectrometry measurements of the neutron-irradiated $^{47}$Ti ampoules revealed that, other than $^{47}$Sc, the long-lived radionuclidic impurity $^{46}$Sc was formed. The amount of generated $^{46}$Sc was influenced by the irradiation period and the neutron energy (Bokhari et al. 2010; Zerkin 2016) and ranged from 3.8 to 11.5% $^{46}$Sc for the irradiations at SINQ (Additional file 1: Figure S3). Considerably less $^{46}$Sc (0.05%) was produced by the irradiation at the BR2 reactor, however. In view of the high percentage of co-produced $^{46}$Sc and the relatively low $^{47}$Sc production yield at both facilities, the production of sufficiently high $^{47}$Sc activities for radiopharmaceutical applications was not considered feasible and, thus, chemical isolation of $^{47}$Sc from neutron irradiated $^{47}$Ti targets was not performed.

Production of $^{47}$Sc from $^{46}$Ca via the (n,\(\gamma\)) reaction

The irradiation of $^{46}$Ca targets with thermal neutrons resulted in the formation of $^{47}$Ca, which decayed to $^{47}$Sc and yielded 210–2140 MBq $^{47}$Sc at the time the separation was performed. The $^{47}$Sc saturation yield was determined by taking the mass of $^{46}$Ca, the irradiation time ($t_{\text{irr}}$), the decay time after EOI ($t_{\text{wait}}$) and the thermal neutron flux ($\Phi_{\text{th}}$) into account and was within the range of 85–98 MBq $^{47}$Sc/mg $^{46}$Ca $10^{-13}$ n cm$^{-2}$ s$^{-1}$, which is comparable with the calculated $^{47}$Sc saturation yield of 92 MBq $^{47}$Sc/mg $^{46}$Ca $10^{-13}$ n cm$^{-2}$ s$^{-1}$ (summarized in Table 3). $^{47}$Sc is formed during the irradiation but also, however, for some time after the end of irradiation by the decay of $^{47}$Ca. This implies that both the irradiation time ($t_{\text{irr}} = 7.0–11.0$ d) and the elapsed post-irradiation time until the start of the separation ($t_{\text{wait}} = 3.0–12.5$ d) are part of the yield-determining factors. The highest $^{47}$Sc activities under the applied irradiation conditions become accessible at an optimal post irradiation waiting time ($t_{\text{opt}}$) and are represented as relative activity $a(\text{Sc}_{\text{opt}})$ in Table 3. The measured relative $^{47}$Sc activities ($a(\text{Sc}_{\text{meas}})$) are lower than the optimal relative $^{47}$Sc activities ($a(\text{Sc}_{\text{opt}})$), as the separations were performed several days after the optimal waiting time. The variable $f(\text{Sc})$ describes the ratio of the $^{47}$Sc activity at $t_{\text{opt}}$ and the $^{47}$Ca activity at EOI. It can be considered as a measure for the maximal obtainable $^{47}$Sc activity, since both activities are referred to the time point of their maximum. The formulae used for the calculation of $A(\text{Sc}_{\text{calc}}, t_{\text{opt}})$, $a(\text{Sc}_{\text{opt}})$ and $f(\text{Sc})$ are given in Additional file 1: Figure S1 a-d.

| Irradiation | $t_{\text{irr}}$ [d] | $m(\text{Ti})$ [mg] | $A(\text{Sc})$ at EOI [MBq] | $A(\text{Sc}_{\text{opt}})$ [MBq/mg $^{47}$Ti $10^{-13}$ n cm$^{-2}$ s$^{-1}$] | $^{47}$Sc activity at EOI [%] |
|-------------|-------------------|-----------------|-------------------|---------------------------------|------------------|
| PSI 1       | 10.9              | 19.03           | 3.9               | 6.6                             | 7.8              |
| PSI 2       | 18.9              | 15.11           | 4.9               | 10.0                            | 11.5             |
| PSI 3       | 1.5               | 1.31            | 0.07              | 0.07                            | 0.05             |
| SCKCEN      | 7.0               | 0.58            | 4.7               | 1.8                             | 3.8              |

Table 2 Activity and yield of $^{47}$Sc at the end of irradiation (EOI) with fast neutrons (>1 MeV) at SINQ (irradiations PSI 1, PSI 2 and PSI 3) and at the BR2 reactor (irradiation SCKCEN)
The measured relative $^{47}$Sc activities ($a(^{47}$Sc)$_{\text{meas}}$) of the irradiations ILL 1, ILL 5 and SCK.CEN are represented by single data points in Fig. 3. After an optimal post irradiation waiting time ($t_{\text{opt}}$) of 2.8 days, the relative $^{47}$Sc activity ($a(^{47}$Sc)$_{\text{opt}}$) reaches the maximum with 0.43. The separations ILL 1 and ILL 5 were performed after waiting times of 6.7 and 6.8 days, resulting in lower relative $^{47}$Sc activities of 0.34 and 0.37, respectively. The waiting time after the irradiation at SCK.CEN (3.0 days) is close to $t_{\text{opt}}$, thus the obtained relative $^{47}$Sc activity of 0.44 is comparable with the optimum value.

### Separation of $^{47}$Sc from $^{46}$Ca and $^{47}$Ca

After the ampoule was crushed, it was moved to the hot cell containing the production panel (Fig. 2), where the target material was dissolved by repeated application of 6.5 mL 3.0 M HCl. The $^{46}$Ca and $^{47}$Sc activity was transferred from the crushed glass ampoule to the DGA column, leaving only 1.1 ± 0.5% $^{47}$Sc and 3.3 ± 0.4% $^{47}$Sc attached to the glass. Direct application of 2 mL 3.0 M HCl quantitatively removed the Ca ($^{47}$Ca and stable Ca isotopes) from the resin. The collected Ca fraction contained 99.8 ± 0.2% of the total $^{47}$Ca activity. The $^{47}$Sc activity was eluted from the DGA column with 4 mL 0.1 M HCl and

| Irradiation | $t_{\text{irr}}$ [d] | $t_{\text{wait}}$ [d] | $t_{\text{opt}}$ [d] | $m(^{46}$Ca) [mg] | $A(^{47}$Sc)$_{\text{at separation}}$ [MBq] | $A(^{47}$Sc)$_{\text{calc}}$ | $A(^{47}$Sc)$_{\text{meas}}$ | $a(^{47}$Sc)$_{\text{opt}}$ | $a(^{47}$Sc)$_{\text{meas}}$ | $f(^{47}$Sc) |
|-------------|----------------------|------------------------|----------------------|-------------------------------------------------|--------------------------|-----------------|----------------|-----------------|----------------|----------------|
| ILL 1       | 7.0                  | 6.7                    | 2.8                  | 0.17                                            | 690                      | 92              | 86              | 0.43            | 0.34            | 0.65           |
| ILL 2       | 7.2                  | 6.7                    | 2.7                  | 0.35                                            | 1390                     | 92              | 85              | 0.44            | 0.34            | 0.66           |
| ILL 3       | 8.4                  | 12.5                   | 2.4                  | 0.14                                            | 470                      | 92              | 98              | 0.50            | 0.25            | 0.69           |
| ILL 4       | 11.0                 | 6.9                    | 1.8                  | 0.35                                            | 2140                     | 92              | 95              | 0.62            | 0.49            | 0.76           |
| ILL 5       | 7.0                  | 6.8                    | 2.8                  | 0.17                                            | 1440                     | 92              | 93              | 0.43            | 0.37            | 0.65           |
| SCK.CEN     | 7.0                  | 3.0                    | 2.8                  | 0.17                                            | 200                      | 92              | 90              | 0.43            | 0.42            | 0.65           |
only 1.5 ± 0.6% of the $^{47}$Sc activity remained on the column. Using Method A, the solution was concentrated on the SCX cation exchange resin (used as the second column) and eluted with 700 μL 4.8 M NaCl/0.1 M HCl solution (pH 0–0.5), collecting 94.8 ± 2.1% of the total $^{47}$Sc activity. When using Method B, the molarity of the $^{47}$Sc eluate was increased from 0.1 to 3.0 M HCl and the resulting solution adsorbed on a second smaller DGA column and eluted with 1.7 mL 0.05 M HCl. Fractionized collection revealed that about ~90% of the eluted $^{47}$Sc activity was obtained in the first 700 μL (pH ~0).

With the installation of the chemical separation system in a hot cell, yields of up to 1.9 GBq $^{47}$Sc could be isolated from the irradiated $^{46}$Ca target. The renewed generation of $^{47}$Sc from the β−-decay of $^{47}$Ca ($T_{1/2} = 4.54$ d) in the Ca-containing fraction, reached the maximum $^{47}$Sc activity after an in-growth period of 5.6 days (Fig. 4) and, thus, enabled repeated separations. As a result of experimental conditions, separations were performed after an in-growth time of 3–7 days. The separation process was successfully repeated 2–4 times, until the eluted $^{47}$Sc activity was ~100 MBq.

Radionuclidic purity of $^{47}$Sc produced from $^{46}$Ca via (n,γ) reaction

The γ-ray spectrum of the neutron-irradiated $^{46}$Ca target material (Additional file 1: Figure S2a) showed, exclusively, the γ-lines of $^{47}$Sc (159 keV) and the parent nuclide $^{47}$Ca (489, 808 and 1297 keV). After chemical separation and concentration of $^{47}$Sc on SCX resin (Method A), the radionuclidic purity of the final $^{47}$Sc eluate was 99.6 ± 0.7%. When the second DGA column (Method B) was used, the radionuclidic purity increased to 99.99 ± 0.03% (Additional file 1: Figure S2b). The long-lived radionuclidic impurity $^{46}$Sc was only present in the eluate obtained from the first separation at a maximum of 0.005% and could be only detected by performing long-term γ-spectrometry measurements several days post separation. The isolated $^{47}$Sc which was generated by the decay of $^{47}$Ca in the Ca-containing fraction did not contain any $^{46}$Sc, due to its entire removal within the first separation.

Fig. 4 The radioactive decay of the parent nuclide $^{46}$Ca ($T_{1/2} = 4.54$ d) to the daughter nuclide $^{47}$Sc ($T_{1/2} = 3.35$ d) reaches the maximum of $^{47}$Sc activity after 135 h (5.6 d). The grey-shaded area indicates the time frame wherein the next separation was performed.
Radiolabeling and stability of ⁴⁷Sc labeled DOTANOC

Radiolabeling of ⁴⁷Sc was reproducible at a specific activity of 10 MBq ⁴⁷Sc per nmol DOTANOC, with >96% radiochemical purity. Depending on the activity concentration of the ⁴⁷Sc solution, it was also possible to label at higher specific activity of up to 25 MBq/nmol.

The stability of ⁴⁷Sc-labeled DOTANOC in PBS (pH 7.4) was investigated over a period of 3 days and compared to the stability of the ¹⁷⁷Lu-labeled analogue (Fig. 5). Directly after the radiosynthesis of ⁴⁷Sc with DOTANOC, the amount of intact radiolabeled product was 96.6–99.0% with less than 2% of radiolysis products visible as pre-peaks on the HPLC chromatogram. After 1 day at room temperature, the amount of intact radiolabeled ⁴⁷Sc-DOTANOC decreased to 81.3%, while 18.3% were subjected to radiolysis. Over the whole investigation period of 3 days, the percentage of radiolysis products increased to 44.4%, however, the amount of free ⁴⁷Sc was always below 2.1%.

The stability of ⁴⁷Sc-labeled DOTANOC was found to be comparable with the clinically-used analogue ¹⁷⁷Lu-DOTANOC. After 3 days, the amount of intact ⁴⁷Sc-DOTANOC (54.1%) was similar to the amount of intact ¹⁷⁷Lu-DOTANOC (43.2%).

Imaging with ⁴⁷Sc-DOTANOC in comparison to ⁴⁴Sc-DOTANOC and ¹⁷⁷Lu-DOTANOC

SPECT/CT experiments performed with AR42J tumor-bearing mice allowed excellent visualization of the accumulated ⁴⁷Sc-DOTANOC in tumor xenografts, which express the somatostatin receptor (Fig. 6a). Activity accumulation was also observed in the kidneys, which was due to renal excretion of the radiopeptide. The SPECT/CT image obtained with ⁴⁷Sc-DOTANOC showed an equal activity distribution profile as was previously demonstrated by a PET/CT scan of an AR42J tumor-bearing mouse 3 h after injection of ⁴⁴Sc-DOTANOC (Fig. 6b) (Domnanich et al. 2016).

To compare the image quality of ⁴⁷Sc with the clinically-employed ¹⁷⁷Lu, mice with AR42J tumors were injected with either ⁴⁷Sc- or ¹⁷⁷Lu-labeled DOTANOC and scanned 6 h after injection (Fig. 7). Both images visualized the uptake of the radiopeptides in tumor xenografts located on each shoulder of the mouse and in the kidneys.
The distribution pattern was equal for both radiopeptides, as expected, based on similar coordination of $^{47}$Sc and $^{177}$Lu when using DOTA.

**Discussion**

Recently, the use of $^{47}$Sc for therapeutic purposes, as part of the $^{44}$Sc/$^{47}$Sc theragnostic radionuclide pair, has attracted considerable attention in the field of nuclear medicine (Rösch and Baum 2011). In the present study we report, to our knowledge, the first reproducible production of MBq to GBq activities of $^{47}$Sc by the irradiation of enriched $^{46}$Ca target material with thermal neutrons. Concurrently, an alternative production route was investigated, using $^{47}$Ti as target material and, by irradiation with fast neutrons, $^{47}$Sc was formed via the (n,p) nuclear reaction. Irradiation of enriched $^{47}$Ti target material with thermal neutrons. Concurrently, an alternative production route was investigated, using $^{47}$Ti as target material and, by irradiation with fast neutrons, $^{47}$Sc was formed via the (n,p) nuclear reaction. Irradiation of enriched $^{47}$Ti target material was performed previously by Mausner and Kolsky in the fission neutron spectrum of the HFIR reactor in Oak Ridge National Laboratory (ORNL) and Brookhaven National Laboratory (BNL) (Kolsky et al. 1998, Mausner, Kolsky et al. 1998) and by Bartoś et al. at the Maria reactor in Świerk, Poland (Bartoś et al. 2012). The reported activity of produced $^{47}$Sc was within the range of 1.4–4.2 MBq $^{47}$Sc/mg $^{47}$Ti $10^{-13}$ n cm$^{-2}$ s$^{-1}$, which is comparable with the $^{47}$Sc radioactivity obtained in our experiment at BR2. The irradiations at SINQ generated higher $^{47}$Sc activities, due to the larger proportion of fast neutrons (> 1 MeV) at the spallation source (Lehmann 2016) than at the reactor.

![Fig. 6](image_url) In vivo SPECT/CT scan of a tumor-bearing mouse 3 h after injection of $^{47}$Sc-DOTANOC (~12 MBq, ~1.2 nmol) (a). In vivo PET/CT scan of a tumor-bearing mouse 3 h after injection, $^{44}$Sc-DOTANOC (~10 MBq, ~1 nmol), image reproduced from Domnanich et al. 2016 (Domnanich et al. 2016) (b). The scan durations were 35 min and 20 min, respectively (Tu = AR42J tumor xenograft, Ki = kidney, Bl = urinary bladder).
The production of 85–98 MBq ⁴⁷Sc/mg ⁴⁶Ca 10⁻¹³ n cm⁻² s⁻¹ was feasible via the ⁴⁶Ca(n,γ)⁴⁷Ca → ⁴⁷Sc route with thermal neutrons from nuclear reactors at ILL and BR2, however. The nearly ten-fold higher accessible ⁴⁷Sc activity from ⁴⁶Ca irradiations can be attributed to the higher nuclear cross section of the ⁴⁶Ca(n,γ)⁴⁷Ca reaction (σ = 0.7 barn) (Magill et al. 2015) in comparison to the ⁴⁷Ti(n,p)⁴⁷Sc nuclear reaction (Additional file 1: Figure S4), as well as to an increased flux of thermal neutrons in comparison to fast neutrons. Lower measured relative ⁴⁷Sc activities than the optimal activities were obtained for the irradiations ILL 1–ILL 5, because the post-irradiation waiting period was too long and the built up ⁴⁷Sc already started to decay. Shorter waiting periods were prevented due to logistical issues. The waiting period after the irradiation at SCK.CEN, however, was close to the optimum time period, thus the measured relative ⁴⁷Sc activity obtained from the irradiation at SCK.CEN is in good correlation with the optimal value.

γ-spectra of the irradiated ⁴⁶Ca indicated the presence of ⁴⁷Ca and ⁴⁷Sc, however, due to high dead time a precise determination of both activities before separation was not possible. After chemical separation a product of high radionuclidic purity, containing only 0.005% ⁴⁶Sc, was obtained (Additional file 1: Figure S2). The acquired radionuclide inventory of ⁴⁷Ti targets, neutron irradiated at the spallation source SINQ, indicated a higher percentage of ⁴⁶Sc (Additional file 1: Figure S3), which increased proportionally with irradiation time (3.8–11.5% ⁴⁶Sc for 1.5–18.9 days irradiation), whereas a significantly smaller amount of ⁴⁶Sc (0.05%) was produced after 7 days of irradiation at the BR2 reactor (SCK.CEN). Trace activities of ¹²²Sb and ¹²⁴Sb were identified in the γ-ray spectrum of the irradiated ⁴⁷Ti ampoule at SINQ (Additional file 1: Figure S3), conceivably produced by neutron activation reactions on natural Sb impurities (Additional file 1: Table S5). The presence of ²²Na and ⁷Be can be attributed to
spallation reactions with the capsulation material. The scan for trace metals revealed impurities of Ca, Sr, Sb and Zr in the reduced $^{47}$Ti metal (Additional file 1: Table S5), which were probably introduced by the reduction process. Neutron activation reactions were only observed with Sb, but not with any of the other determined impurities, however.

The formation of $^{46}$Sc from $^{47}$Ti via the $^{47}$Ti(n,n + p)$^{46}$Sc nuclear reaction is known to be only induced by very fast neutrons above the threshold of 10.7 MeV (Additional file 1: Figure S4) (Zerkin 2016). The considerably decreased $^{46}$Sc impurity of the sample irradiated at the BR2 reactor can, therefore, be attributed to the lower proportion of very energetic neutrons in the fission spectrum of the BR2 reactor (Chrysanthopoulou et al. 2014), compared to the spallation neutron spectrum in the SINQ (Lehmann 2016). The percentage of $^{46}$Sc obtained from the $^{47}$Ti irradiation at the BR2 reactor was in agreement with those from previous experiments at ORNL, BNL and the Maria reactor, which was reported to be 0.06–0.64% $^{46}$Sc (Kolsky et al. 1998; Mausner et al. 1998; Bartoś et al. 2012). With respect to radio-pharmaceutical applications, the ten-fold higher $^{47}$Sc production from $^{46}$Ca targets, together with the absence of long-lived radionuclidic impurities, intensified our research towards the further development of the more attractive $^{46}$Ca route.

In order to meet the requirements for radio-pharmaceutical applications, the obtained $^{45}$Sc eluate needed to be of high chemical purity and concentrated into a small volume of moderately acidic eluate to facilitate efficient radiolabeling and subsequent in vivo application. Initially, SCX cation exchange resin (Method A) was used and 94.8% ± 2.1% of the total $^{47}$Sc activity was recovered in only 700 μL eluate (4.8 M NaCl/0.1 M HCl). The use of this resin is already established for the concentration of the $^{68}$Ga eluate from the $^{68}$Ge generator (Mueller et al. 2013); however, direct preclinical in vivo application is not feasible due to the high osmolarity of the obtained eluate. In a modification of the separation procedure, a second, smaller DGA column was used (Method B), allowing the elution of ~90% using 700 μL 0.05 M HCl. This enabled labeling and preclinical application as previously shown with $^{44}$Sc (Domnanich et al. 2016).

The labeling of DOTANOC with $^{47}$Sc was performed to verify a consistent chemical purity of the obtained eluate. Our results demonstrated reproducible radiosynthesis of $^{47}$Sc-DOTANOC at specific activities of 10 MBq/nmol, whereas radiolabeling at 25 MBq/nmol proved possible. The obtained results indicated good quality of the produced $^{47}$Sc achieving radiolabeling yields, in agreement with the previously-performed $^{47}$Sc-radiolabeling of a DOTA-folate conjugate (Müller et al. 2014a).

In PBS $^{47}$Sc remained stably coordinated by the DOTA-chelator over 3 days (<6% release), a result which was comparable to the $^{177}$Lu-labeled peptide. $^{47}$Sc- and $^{177}$Lu-DOTANOC were, however, affected by radiolytic decomposition, which decreased the amount of intact product over time. It is likely the radiolytic stability could be enhanced by the addition of radical scavengers, such as ascorbic or gentisic acids, which were previously successfully employed for the stabilization of $^{90}$Y- and $^{177}$Lu-labeled DOTA-peptides (Liu and Edwards 2001; Liu et al. 2003).

In a proof-of-concept study, $^{47}$Sc-DOTANOC was utilized for SPECT/CT imaging of AR42J tumor-bearing mice. The equal distribution profile of $^{47}$Sc-DOTANOC and $^{48}$Sc-DOTANOC, previously demonstrated using PET/CT, demonstrated the successful realization of the “matched pair” principle using scandium radionuclides. Moreover, the
in vivo distribution of $^{47}$Sc-DOTANOC was comparable to $^{177}$Lu-DOTANOC. Due to the higher percentage of emitted γ-radiation in the case of $^{47}$Sc, it is expected that less activity of $^{47}$Sc-labeled compounds would be necessary for clinical SPECT as compared to the activity necessary for $^{177}$Lu-labeled counterparts.

**Conclusions**

The reproducible production of activities of up to 2 GBq $^{47}$Sc at high radionuclidic purity via the $^{46}$Ca(n,γ)$^{47}$Ca nuclear reaction in the thermal neutron flux of a reactor was demonstrated. The subsequent decay of $^{47}$Ca to $^{47}$Sc creates a “pseudo-generator” system, which enables the repeated separation of the $^{47}$Sc daughter nuclide from the $^{47}$Ca parent nuclide. Together with the high radionuclidic purity and the superior yield of the isolated $^{47}$Sc activity, the $^{46}$Ca production route bears significant advantages over the $^{47}$Ti production route with fast neutrons. Even though the high price of enriched $^{46}$Ca represents a drawback, implementation of a suitable recovery method will limit the expenses. Based on the results obtained from this proof-of-concept study, $^{47}$Sc has the potential to be produced in a suitable quality for clinical applications, however, the quantity of radioactivity still needs to be expanded to meet the requirements for radio-nuclide therapy.

**Additional file**

Additional file 1: Figure S1a. Formula for the calculation of the $^{47}$Sc activity in Bq (s$^{-1}$), accessible under the applied irradiation conditions. $\sigma =$ nuclear cross section of the $^{46}$Ca(n,γ)$^{47}$Ca reaction in cm$^{-2}$, $N_0 =$ number of $^{46}$Ca atoms, $\Phi_{th} =$ thermal neutron flux in n * cm$^{-2} * s^{-1}$, $\lambda_{Sc}$ and $\lambda_{Ca} =$ decay constants of $^{47}$Sc and $^{47}$Ca in s$^{-1}$, $t_{irr} =$ irradiation time and $t_{wait} =$ post irradiation waiting time in s. b Formula for the calculation of the optimal post irradiation waiting time (t$_{wait}$) in s, accessible at the applied irradiation time (t$_{irr}$) in s. The decay constants of $^{47}$Sc ($\lambda_{Sc}$) and $^{47}$Ca ($\lambda_{Ca}$) are given in s$^{-1}$. c Formula for the calculation of the optimal relative $^{47}$Sc activity (a($^{47}$Sc)opt) (dimensionless), accessible under the applied irradiation conditions. $\sigma =$ nuclear cross section of the $^{46}$Ca(n,γ)$^{47}$Ca reaction in cm$^{-2}$, $N_0 =$ number of $^{46}$Ca atoms, $\Phi_{th} =$ thermal neutron flux in n * cm$^{-2} * s^{-1}$, $\lambda_{Sc}$ and $\lambda_{Ca} =$ decay constants of $^{47}$Sc and $^{47}$Ca in s$^{-1}$. d Formula for the maximal obtainable $^{47}$Sc activity (dimensionless). The irradiation time (t$_{irr}$) is given in s and the decay constants of $^{47}$Sc ($\lambda_{Sc}$) and $^{47}$Ca ($\lambda_{Ca}$) in s$^{-1}$. Figure S2. γ-Ray spectra of $^{47}$Sc and $^{47}$Ca from the neutron-irradiated $^{46}$Ca ampoule, obtained 71 h after the end of irradiation (measurement time: 10 s) (a) and of the pure $^{47}$Sc eluate after separation (Method B), obtained 1 h after the end of separation (measurement time: 250 s) (b). Figure S3. γ-Ray spectrum of the neutron-irradiated $^{47}$Ti ampoule at SINQ, obtained 21 d after the end of irradiation (measurement time: 9600 s). Figure S4. Measured cross section values (squares, retrieved from the EXFOR-database) (Zerkin 2016) as well as the theoretical calculations from the TENDL-2015 library (straight line) (Koning, Rochman et al. 2015) for the $^{47}$Ti(n,p)$^{47}$Sc (blue) and the $^{47}$Ti(n,p+n)$^{46}$Sc (black) nuclear reactions. Table S5. Trace metal analysis of the reduced $^{46}$Ti metal by ICP-OES. Only the elements determined at a concentration higher than the detection limit are listed below. (DOCX 415 kb)

**Acknowledgments**

We thank Raffaella Schmid, Renata Farkas, Walter Hirzel and Muhamed Djelili for technical assistance.

**Funding**

The research was funded by the Swiss National Science Foundation (CR23I2_156852).

**Authors’ contributions**

KAD developed the production and separation process, performed the separation experiments of $^{47}$Sc, did the radiolabeling and the stability experiments, analyzed the data and drafted the manuscript. CM was responsible for the performance of the in vitro and in vivo studies and revised the manuscript. MB supported the $^{47}$Sc separation process and reviewed the manuscript. SH performed the in vivo studies. UK and BP were responsible for the irradiation of $^{46}$Ca targets and $^{47}$Ti targets at ILL and SCK.CEN, respectively. AT and RD assisted with the yield and irradiation calculations, while AT also reviewed the manuscript. RS reviewed the manuscript. NvdM was responsible for the development of the production and separation process of $^{47}$Sc, supervised the whole study and finalized the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.
Ethics approval
This article does not contain any studies with human participants performed by any of the authors. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Laboratory of Radiochemistry, Paul Scherrer Institut, 5232 Villigen-PSI, Switzerland. 2Department of Chemistry and Biochemistry University of Bern, 3012 Bern, Switzerland. 3Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut, 5232 Villigen-PSI, Switzerland. 4Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland. 5Institut Laue-Langevin, 38000 Grenoble, France. 6SCK.CEN, BR2 Reactor, 2400 Mol, Belgium.

Received: 13 March 2017 Accepted: 12 May 2017
Published online: 02 June 2017

References
Bartoń B, Majkowska A, Kasperek A, Krajewski S, Bilewicz A. New separation method of no-carrier-added $^{47}$Sc from titanium targets. Radiochim Acta. 2012;100(7):457–61.
Baum RP, Kulkami HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy—The Bad Berka Experience: Theranostics. 2012;25:437–47.
Bokhvari TH, Mustafa A, Khan IL. Separation of no-carrier-added radioactive scandium from neutron irradiated titanium. J Radioanal Nucl Chem. 2010;283(2):389–93.
Chakravarty R, Goel S, Valdivinos HF, Hernandez R, Hong H, Nikles RJ, Cai W. Matching the Decay Half-Life with the Biological Half-Life: ImmunoPET Imaging with $^{47}$Sc-Labeled Cetuximab Fab Fragment. Bioconjug Chem. 2014;25(12):2197–204.
Chrysanthopoulou N, Savva P, Varvayanni M, Catsaros N. “Compilation of Existing Neutron Screen Technology”. Science and Technology of Nuclear Installations. 2014.
Domnanich KA, Müller C, Farkas R, Schmid RM, Ponsard B, Schibli R, Türler A, Van der Meulen N. $^{46}$Sc: for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. EJNMMI Radiochem. 2016(8):19.
García-Torano E, Peyres V, Roteta M, Sanchez-Cabezudo AI, Romero E, Martinez Ortega A. Standardisation and precise determination of the half-life of $^{47}$Sc. Appl Radiat Isot. 2016;109:314–8.
Hernandez R, Valdivinos HF, Yang Y, Chakravarty R, Hong H, Bamhart TE, Cai W. $^{46}$Sc: an attractive isotope for peptide-based PET imaging. Mol Pharm. 2014;11(8):2954–61.
Kolsky KL, Joshi V, Mausner LF, Srivastava SC. Radiochemical purification of no-carrier-added Scandium-47 for radionuclide therapy. Appl Radiat Isot. 1998;49(12):1541–9.
Kraeber-Bodere F, Barbet J. Challenges in nuclear medicine: innovative theranostic tools for personalized medicine. Front Med (Lausanne). 2014;1:16.
Lehmann, E. 2016. “https://www.psi.ch/nis/parameters.” Accessed 2 Dec 2016.
Liu S, Edwards DS. Stabilization of $^{99m}$Tc-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjug Chem. 2003;14(5):1052–8.
Lommel B, Beusch A, Hartmann W, Hubner A, Kindler B, Steiner J, Yakusheva V. Reduction of isotopically enriched $^{50}$Ti-dioxide for the production of high-intensity heavy-ion beam. J Radioanal Nucl Chem. 2014;299(3):781–80.
Magill J, Pfirnning G, Dreher R, Soti Z. Karlsruher Nuklidkarte/Chart of the Nuclides. Eggenstein-Leopoldshafen: Nucleonica GmbH. 2015.
Majkowska-Pilip A, Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem. 2011;105(2):313–20.
Mamtimin M, Harmon F, Starońtowana VN. Sc-47 production from titanium targets using electron linacs. Appl Radiat Isot. 2015;102:1–4.
Mausner LF, Kolsky KL, Joshi V, Srivastava SC. Radionuclide development at BNL for nuclear medicine therapy. Appl Radiat Isot. 1998;49(4):285–94.
Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, Türler A, Schibli R. Direct in vitro and in vivo investigations of the biological half-life of $^{44}$Sc-DOTA-folate conjugate. J Nucl Med. 2013b;54(1):124–30.
Müller C, Bunka M, Haller S, Köster U, Groehn V, Bernhardt P, van der Meulen N, Türler A, Schibli R. Promising prospects for $^{47}$Sc-/47Sc-based theragnostics: application of $^{47}$Sc for radionuclide tumor therapy in mice. J Nucl Med. 2014a;55(10):1658–64.
Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, Türler A, Schibli R. Direct in vitro and in vivo comparison of $^{194}$Tb and $^{177}$Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014b;41(3):476–85.
Oh S, Prasad V, Lee DS, Baum RP. Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging. 2011;2011:524130.
Parus JL, Pawlak D, Mikołajczak R, Duatti A. Chemistry and bifunctional chelating agents for binding $^{177}$Lu. Curr Radiopharm. 2015;8(2):86–94.
Rane S, Harris JT, Starovoitova VN. $^{47}$Ca production for $^{47}$Ca/$^{47}$Sc generator system using electron linacs. Appl Radiat Isot. 2015;97:188–92.
Reubi JC, Schar JC, Waser B, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.
Rösch F. Scandium-44: benefits of a long-lived PET radionuclide available from the $^{44}$Ti/$^{44}$Sc generator system. Curr Radiopharm. 2012;5(3):187–201.
Rösch F, Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011;40(23):6104–11.
Srivastava SC. Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory. Semin Nucl Med. 2012;42(3):151–63.
Starovoitova VN, Cole PL, Grimm TL. Accelerator-based photoproduction of promising beta-emitters $^{67}$Cu and $^{47}$Sc. J Radioanal Nucl Chem. 2015;305:127–32.
vander Meulen NP, Bunka M, Domnanich KA, Müller C, Haller S, Vermeulen C, Türler A, Schibli R. Cyclotron production of $^{44}$Sc: From bench to bedside. Nucl Med Biol. 2015;42(9):745–51.
Velikyan I. Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics. 2012;2(5):424–6.
Vila-Villegas N, Doyle RP. The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (H4DOTA): Structural overview and analyses on structure-stability relationships. Coord Chem Rev. 2009;253(13-14):1906–25.
Walczak R, Krajewski S, Szklarz K, Sitarz M, Abbas K, Choisnki J, Jakubowski A, Jastrzebski J, Majkowska A, Simonelli F, Stolarz A, Trzcińska A, Zipper W, Blievicz A. Cyclotron production of $^{45}$Sc for PET imaging. EJNMMI Physics. 2015;2(1):10.
Yagi M, Kondo K. Preparation of Carrier-free $^{47}$Sc by the $^{48}$Ti(γ,p) Reaction. Int J Appl Radiat Isot. 1977;28(5):463–8.
Zerkin V. “Experimental Nuclear Reaction Data (EXFOR).” Retrieved 05.12. 2016. from https://www-nds.iaea.org/exfor/exfor.htm.